Manufacturing of the first products of the medicinal product workshop of the Cherkasy Milk Processing Factory, one of the best USSR enterprises among the equivalent ones. The main product was Hycase SF blood substitute. The rated capacity was 1,500 tonnes per year.
Establishment of Yuria CJSC on the basis of the medicinal product workshop.
Establishment of Yuria-Pharm LLC. The new team of the company launched a set of anti-crisis measures designated for extension of the product line, improvement of the management model and staff qualifications.
Extension of the product portfolio which included glucose solutions, neohaemodes, novocaine solution, rheopolyglucin, sodium chloride, Ringer’s solution as well as ofloxacin, fluconazole and ciprofloxacin solutions.
Industrial manufacturing of Rheosorbilact®, an innovative product which was a breakthrough in the present-day infusion therapy, was launched. The new company history started with the launch of Rheosorbilact®: it was the very product which turned into the main brand identity of Yuria-Pharm LLC for many years.
Bosch и Bausch Strobel automatic lines, which enabled increasing of productive efficiency dozens of times, were installed. Trust to the products of Yuria-Pharm LLC grew: more than two million vials of products were sold in Ukraine in 2003.
The first export of products to the CIS countries: Uzbekistan, Georgia, Russia, and Moldova.
We established our own distribution service to get closer to our customers. Thousands tonnes of essential products are daily sent to consumers from warehouses all over Ukraine.
In 2007, Yuria-Pharm Corporation launched a new revolutionary product to the market: double-tipped syringes. Although it was forbidden to use the same needle to fill a syringe and make an injection in other countries, it was a novelty for Ukraine.
The year was marked by the launch of industrial manufacturing of Tivortin, the product which became irreplaceable in treatment of vascular malformations in a couple of years.
The first foreign representative office was opened (Uzbekistan).
The First Strategic Session to determine the company focus area for the next five years was held.
The Certificate of Conformity to International Quality Management Standards ISO 9001–2001 was obtained.
Victory in the annual Panacea contest in nomination The Leader of the Infusion Products Market in Ukraine. According to the results of 2008, Yuria-Pharm Corporation provided for approximately 30 % of Ukrainian demand for hospital solutions.
Victory of Rheosorbilact in the annual Panacea contest in nomination Scientific Achievement of Ukraine.
Manufacturing of pre-filled syringes was launched.
Bottelpack equipment for production of polymeric containers was installed. Production of new pharmaceutical forms, nebula and ampule, was launched.
The Certificate of GMP Compliance was obtained.
Yuria-Pharm Corporation was the first CIS representative to take part in the European Respiratory Society (ERS) congress in Vienna (Austria). Dekasan, the first pulmonary antiseptic agent, was found to be one of the most interesting novelties of the congress.
The representative office YURiA-PHARM EAST AFRICA LTD was opened (Uganda, Kenya, Tanzania, Ruanda, South Sudan).
Transformation of the national company into the international Corporation entering new foreign markets. Representative offices in Kazakhstan, Tajikistan, Vietnam and Russia were opened.
Leadership in the hospital segment (ranked second as to the scope of hospital procurements).
International ISLQ (International Star for Leadership in Quality) Award in the gold category from Business Initiative Directions.
BEST QUALITY LEADERSHIP AWARD 2014 in the GOLD CATEGORY.